A Randomized, Investigator and Participant Blinded, Placebo Controlled, Multiple Ascending Dose, Two Part Design Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of MHS552 in Adults With Type 1 Diabetes Mellitus (T1DM)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 10 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MHS 552 (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions
Sponsors Novartis Pharmaceuticals

Most Recent Events

05 Apr 2023 Status changed from not yet recruiting to withdrawn prior to enrolment on sponsor's decision.
15 Mar 2023 Planned initiation date changed from 13 Feb 2023 to 1 Sep 2023.
28 Sep 2022 Planned End Date changed from 30 Dec 2024 to 14 Apr 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight